Cancer treatment could identify patients most likely to respond to cancer drugs
Tumours with high mtDNA mutations more likely to respond to Opdivo
Read More
Tag: nivolumab
Positive results for Ipsen’s Cabometyx in combination with nivolumab
Benefits were identified with Cabometyx in combination with nivolumab across all efficacy measures
Read More
NICE ‘no’ for Opdivo/Yervoy lung cancer combo
The combination is not considered to be a cost-effective use of NHS resources in this setting
Read More
BMS’ Opdivo wins new NICE lung cancer backing
The drug has been approved for routine NHS commissioning for squamous or non-squamous NSCLC
Read More
Opdivo/Cabometyx combo hits targets in first-line kidney cancer
The combination significantly increased progression free survival when used as a first-line treatment
Read More
FDA, EMA accept Opdivo-Yervoy filings in lung cancer
The filing is based on data from the CheckMate-9LA trial, which showed a benefit in overall survival
Read More
BMS’ Opdivo disappoints in late-stage trial
However, a clear trend was demonstrated towards improvement in overall survival.
Read More
Promising early results for BMS’ investigational HCC study
The company are “encouraged by these early results”, as liver cancer affects over 5,700 new patients in the UK each year.
Read More
Opdivo shows promising results in Phase I/II trial
An early-stage trial has shown promising results for Bristol-Myers Squibb’s Opdivo in combination with Nektar Therapeutics’ bempegaldesleukin as first-line treatment for urothelial carcinoma.
Read More
SMC accepts four medicines for NHS use
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.
Read More
NICE turns down Opdivo/Yervoy combo for kidney cancer
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma.
Read More
NICE u-turn on Opdivo for skin cancer recurrence
NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence after surgery has now been approved by the National Institute for Health and Care Excellence
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
